At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,484 enrolled
Drug / intervention
Mirikizumab +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of Mirikizumab to Secukinumab and Placebo in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-2
In Brief
A Phase 3 clinical trial evaluating Mirikizumab, Placebo, and 1 other intervention for Psoriasis. Completed, enrolled 1,484 participants across 178 sites in 16 countries.
Detailed Summary
The reason for this study is to see how effective and safe mirikizumab is compared to secukinumab and placebo for moderate to severe plaque psoriasis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis
CountriesArgentina, Australia, Canada, Czechia, France, Germany, Hungary, Israel, Italy, Japan, Poland, Puerto Rico, South Korea, Spain, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20192020202120222023202420252026
First PostedMay 2018
Enrollment StartJun 2018
Primary CompletionMar 2020
Study CompletionJun 2020
TodayJul 2026
First PostedMay 24, 2018
Enrollment StartJun 26, 2018
Primary CompletionMar 5, 2020
Study CompletionJun 3, 2020
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 8.1 years ago
Interventions
Mirikizumabdrug
Administered SC
Placebodrug
Administered SC
Secukinumabdrug
Administered SC